Skip to main content Skip to navigation

Overview

The BD OneFlow™ LST is part of the innovative BD OneFlow™ Solution, a comprehensive set of reagents, setup beads, protocols and assay templates to reproducibly set up the flow cytometer and stain, acquire and analyze patient specimens for immunophenotyping of normal and aberrant cell populations. It is built on the research and validation work of the EuroFlow™ Consortium on the characterization of hematological malignancies for improved accurate diagnosis.1

 

The BD OneFlow™ LST is intended for flow cytometric immunophenotyping of normal and aberrant mature lymphocyte populations of B, T and NK cell lineages in peripheral blood, bone marrow and lymph nodes.

 

Other reagents belonging to the BD OneFlow™ Solution are BD OneFlow™ B-CLPD T1, BD OneFlow™ PCST, BD OneFlow™ PCD

performance1

FEATURES

The BD OneFlow™ LST reagent composition

 

AntibodyFluorochromeCloneTarget Populations
CD45BD Horizon V500-C2Dl (anti-HLe-1)Mature lymphocytes, B-cell precursor

CD19

PE-Cy7SJ25-C1B-cells, and NK-cells by exclusion
CD20BD Horizon V450L27B-cells, and NK-cells by exclusion
Anti-LambdaFITC 1-155-2Normal and clonally expanded B cells
Anti-KappaPETB28-2Normal and clonally expanded B Cells
CD38APC-H7HB7Plasma cells and B-cell precursors, Lymphoid malignancies, NK cells
CD3APCSK7T cells, B- and NK-cells by exclusion
CD4BD Horizon™ 450SK3 (Leu-3a)T cell subpopulations
CD8FITCSK1 (Leu-2a)T cell subpopulations
CD5PerCP-Cy5.5L17F12T cell subpopulations
Anti-TCR-1PE-Cy711F2T cell subpopulations
CD56PEMY31 (Leu-19)NK Cells

 

The EuroFlow antibody panel article1* has a full description of the utility of the antibodies chosen for the BD OneFlow™ LST.

 

 

APPLICATIONS

Supporting Evidence

The EuroFlow “LST detected aberrant B-, T-, or NK-cells immunophenotypes in 149/150 (99.4%) of B-CLPD and in 78/83 (94%) of T/NK-CLPD with an overall frequency of 97.4%."1

 

Results from the clinical trial study show that the BD OneFlow™ LST in combination with the BD OneFlow™ B-CLPD T1 gave 100% (101 of 101) overall agreement in classifying patients as having CLL (54 of 54 concordant) and in identifying patients with other B cell chronic lymphoproliferative diseases (47 out of 47 concordant) when compared with the EuroFlow system. Furthermore, interpretation of the BD OneFlow™ Solution results was highly concordant to diagnostic truth.

References

  1. van Dongen JJM, Lhermitte L, Böttcher S, et al. on behalf of the EuroFlow Consortium (EU-FP6, LSHB-CT-2006-018708). EuroFlow antibody panels for standardized n-dimensional flow cytometric immunophenotyping of normal, reactive and malignant leukocytes. Leukemia. 2012;26(9): 1908-1975. doi: 10.1038/leu.2012.120

  2. Moloney E, Watson H, Barge D, et al. Efficiency and health economic evaluations of BD OneFlow™ Flow Cytometry Reagents for diagnosing chronic lymphoid leukemia. Cytometry B Clin Cytom. 2019;96(6):514-520. doi: 10.1002/cyto.b.21779

  3. Kalina T, Flores-Montero J, van der Velden VHJ, et al. EuroFlow standardization of flow cytometer instrument settings and immunophenotyping protocols. Leukemia. 2012;26(9):1986-2010. doi: 10.1038/leu.2012.122
For Research Use Only. Not for use in diagnostic or therapeutic procedures.